CTIM-22. PHASE 1 TRIAL OF OSIMERTINIB WITH STEREOTACTIC RADIOSURGERY (SRS) IN PATIENTS WITH BRAIN METASTASES FROM EGFR POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC)
Publication Date
2020
Presented At:
2020 Society for Neuro-Oncology’s Virtual Annual Scientific Meeting and Education Day
Content Type
Presentation
Publisher's Site:
Citation
Neuro-Oncology (2020) 22(Supplement_2):ii37-ii38